What Happened?
Baltimore, MD-based Personal-Genome-Diagnostics Appointed Jeff Boschwitz as Chief Operating Officer
About the Company
Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu to help bring novel diagnostic approaches to patients with cancer. They are internationally recognized leaders in cancer genomics who have extensive experience in the application of innovative genomic technologies for drug development and clinical practice.
About the Person
Dr. Boschwitz was formerly Executive Vice President, Operations and Corporate Development at cancer pathology company PLUS Diagnostics, where he was responsible for reducing production costs while improving quality and customer satisfaction. Earlier, Dr. Boschwitz was Vice President of North American Sales and Marketing at Orchid Cellmark, a leading provider of human identity testing that was acquired by LabCorp in 2011. Previously, Dr. Boschwitz was Director, Marketing Planning, Analysis, and Research at Quest Diagnostics, where he led strategic planning, new product development and sales targeting for the $5 billion physician business. Earlier in his career, Dr. Boschwitz was a Principal in the healthcare practice of Booz Allen Hamilton. He received BS and PhD degrees from Cornell University and was a Postdoctoral Fellow at Stanford University.
Info Source
Press Release
Short Profile